Non-alcoholic hepatic steatosis and its relation to increased plasma biomarkers of inflammation and endothelial dysfunction in non-diabetic men. Role of visceral adipose tissue

Diabetic Medicine

Volumn 22, Issue 10, 2005, Pages 1354-1358

  Targher, Giovanni ^a,b   Bertolini, L ^a   Scala, L ^a   Zoppini, G ^b   Zenari, L ^a   Falezza, G ^a  

^a SACRO CUORE DON CALABRIA HOSPITAL   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

Endothelial dysfunction; Hepatic steatosis; Metabolic syndrome; Subclinical inflammation; Visceral fat

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIVER ENZYME; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRIACYLGLYCEROL; VON WILLEBRAND FACTOR;

ADIPOSE TISSUE; ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENDOTHELIUM LESION; FATTY LIVER; HOMEOSTASIS; HUMAN; HUMAN EXPERIMENT; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; NORMAL HUMAN; TRIACYLGLYCEROL BLOOD LEVEL;

ADIPOSE TISSUE; ADULT; BIOLOGICAL MARKERS; BLOOD PRESSURE; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; ENDOTHELIUM; FATTY LIVER; FIBRINOGEN; HUMANS; INFLAMMATION; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; PLASMINOGEN ACTIVATOR INHIBITOR 1; TOMOGRAPHY, X-RAY COMPUTED; TRIGLYCERIDES; VON WILLEBRAND FACTOR;

EID: 25844445415     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2005.01646.x     Document Type: Article

References (22)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002; 346: 1221-1231.
2. Harrison SA, Di Bisceglie AM. Advances in the understanding and treatment of nonalcoholic fatty liver disease. Drugs 2003; 63: 2379-2394.
3. Medina J, Fernandez-Salazar LI, Garcia-Buey L, Moreno-Otero R. Approach to the pathogenesis and treatment of nonalcoholic steatohepatitis. Diabetes Care 2004; 27: 2057-2066.
4. Cigolini M, Targher G, Bergamo-Andreis IA, Tonoli M, Agostino G, De Sandre G. Visceral fat accumulation and its relation to plasma haemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 1996; 16: 368-374.
5. Lyon CJ, Law RE, Hsueh WA. Minireview: adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195-2200.
6. Wajchenberg BL. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 2000; 21: 697-738.
7. Cigolini M, Targher G, Agostino G, Tonoli M, Muggeo M, De Sandre G. Liver steatosis and its relation to plasma haemostatic factors in apparently healthy males. Role of the metabolic syndrome. Thromb Haemost 1996; 76: 69-73.
8. Bonora E, Targher G, Alberiche M, Bonadonna RC, Saggiani F, Zenere BM et al. Homeostasis Model Assessment closely mirrors the glucose clamp technique in the assessmnet of insulin sensitivity. Studies in subjects with various degrees of glucose tolerance and insulin sensitivity. Diabetes Care 2000; 23: 57-63.
9. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. J Am Med Assoc 2003; 289: 1799-1804.
10. Nicklas BJ, Ambrosius W, Messier SP, Miller GD, Penninx BW, Loeser RF et al. Diet-induced weight loss, exercise, and chronic inflammation in older, obese adults: a randomized controlled clinical trial. Am J Clin Nutr 2004; 79: 544-551.
11. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997; 27: 103-107.
12. Kugelmas M, Hill D, Vivian B, Marsano L, McClain C. Cytokines and NASH: a pilot study of the effects of lifestyle modification and vitamin E. Hepatology 2003; 38: 413-419.
13. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990; 99: 1408-1413.
14. Palaniappan L, Carnethon MR, Wang Y, Hanley AJG, Fortmann SP, Haffner SM et al. Predictors of the incident metabolic syndrome in adults. The Insulin Resistance Atherosclerosis Study. Diabetes Care 2004; 27: 788-793.
15. Targher G, Bertolini L, Padovani R, Zenari L, Zoppini G, Falezza G. Relation of nonalcoholic hepatic steatosis to early carotid atherosclerosis in healthy men. Role of visceral fat accumulation. Diabetes Care 2004; 27: 1498-1500.
16. Chalasani N, Deeg MA, Persohn S, Crabb DW. Metabolic and anthropometric evaluation of insulin resistance in nondiabetic patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2003; 98: 1849-1855.
17. Marchesini G, Bugianesi E, Forlani G, Cerrelli F, Lenzi M, Manini R et al. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
18. Marchesini G, Brizi M, Bianchi G, Tomasetti S, Zoli M, Melchionda N. Metformin in non-alcoholic steatohepatitis. Lancet 2001; 358: 893-894.
19. Uygun A, Kadayifci A, Isik A, Ozgurtas T, Deveci S, Tuzun A et al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment Pharmacol Ther 2004; 19: 537-544.
20. Neuschwander-Tetri BA, Brunt E, Wehmeier K, Oliver D, Bacon B. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone. Hepatology 2003; 38: 1008-1017.
21. Neuschwander-Tetri BA, Brunt E, Wehmeier K, Sponseller C, Hampton K, Bacon B. Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis. J Hepatol 2003; 38: 434-440.
22. Promrat K, Lutchman G, Uwaifo G, Freedman R, Soza A, Heller T et al. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004; 39: 188-196.